130 Drug Distribution and Control: Preparation and Handling–Guidelines
55. Davis K, Sparks J. Getting started in aseptic com-
pounding. Bethesda, MD: American Society of
Health-System Pharmacists; 2008.
56. Kienle PC. Compounding sterile preparations:
ASHP video guide to chapter <797>. Bethesda, MD:
American Society of Health-System Pharmacists;
2009.
57. U.S. Department of Health and Human Services, Food
and Drug Administration, Office of Regulatory Affairs.
Guidance for industry: sterile drug products produced
by aseptic processing—current good manufacturing
practice. September 2004. www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM070342.pdf (accessed 2012 Dec 28).
58. General notices and requirements. In: The United
States pharmacopeia, 34th rev., and The national for-
mulary, 29th ed. Rockville, MD: The United States
Pharmacopeial Convention; 2011:11–12.
59. Pharmaceutical compounding—nonsterile prepa-
rations (general information chapter 795). In: The
United States pharmacopeia, 34th rev., and The na-
tional formulary, 29th ed. Rockville, MD: The United
States Pharmacopeial Convention; 2011:330–6.
60. Trissel LA. Handbook on injectable drugs. 17th ed.
Bethesda, MD: American Society of Health-System
Pharmacists; 2013.
61. Bing CD, Nowobilski-Vasilios A. Extended stability
for parenteral drugs. 5th ed. Bethesda, MD: American
Society of Health-System Pharmacists; 2013:321.
62. Personal communication from Hospira. December 16,
2008.
63. Personal communication from Baxter. December 18,
2008.
64. Personal communication from B. Braun. December
26, 2008.
65. Injections (general information chapter 1). In: The
United States pharmacopeia, 34th rev., and The na-
tional formulary, 29th ed. Rockville, MD: The United
States Pharmacopeial Convention; 2011:33–8.
66. Centers for Disease Control and Prevention, National
Center for Emerging and Zoonotic Infectious Diseases
(NCEZID), Division of Healthcare Quality Promotion
(DHQP). Safe Injection Practices to Prevent Transmission
of Infections to Patients. www.cdc.gov/injectionsafety/
IP07_standardPrecaution.html (accessed 2013 Jan 30).
67. Sterility tests (general information chapter 71). In: The
United States pharmacopeia, 34th rev., and The na-
tional formulary, 29th ed. Rockville, MD: The United
States Pharmacopeial Convention; 2011:65–70.
68. Bacterial endotoxins test (general information chapter
85). In: The United States pharmacopeia, 34th rev.,
and The national formulary, 29th ed. Rockville, MD:
The United States Pharmacopeial Convention; 2011:
78–82.
69. Pyrogen test (general information chapter 151). In: The
United States pharmacopeia, 34th rev., and The na-
tional formulary, 29th ed. Rockville, MD: The United
States Pharmacopeial Convention; 201
1:115–7.
70. Oversight of Care, Treatment, and Services
Provided through Contractual Agreement (Standard
LD.04.03.09). Comprehensive accreditation manual
for hospitals: the official handbook. Oakbrook Terrace,
IL: The Joint Commission; 2012.
71. Trissel LA, Gentempo JA, Saenz LM, et al. Effect of
two work practice changes on the microbial contami-
nation rates of pharmacy-compounded sterile prepara-
tions. Am J Health-Syst Pharm. 2007; 64:837–41.
72. Sessink PJ, Boer KA, Scheefhals AP, et al.
Occupational exposure to antineoplastic agents at sev-
eral departments in a hospital: environmental contami-
nation and excretion of cyclophosphamide and ifos-
famide in urine of exposed workers. Int Arch Occup
Environ Health. 1992; 64:105–12.
73. Kiffmeyer TK, Ing KG, Schoppe G. External con-
tamination of cytotoxic drug packing: safe handling
and cleaning procedures. J Oncol Pharm Pract. 2000;
6:13.
74. Connor TH, Sessink PJ, Harrison BR et al. Surface
contamination of chemotherapy drug vials and evalu-
ation of new vial-cleaning techniques: results of three
studies. Am J Health-Syst Pharm. 2005; 62:475–84.
75. Kastango ES, Wagner JT, Kastango KB, et al.
Generation of particulate matter during handling
of needle and syringe packaging. Am J Health-Syst
Pharm. 2008; 65:1443–50.
76. OSHA Hazard Communication Standard (revised
2012). www.osha.gov/dsg/hazcom/index.html. (ac-
cessed 2012 Dec 28).
77. National Institute for Occupational Safety and Health
[NIOSH]. Medical surveillance for healthcare workers
exposed to hazardous drugs. NIOSH Publication No.
2013-103; November 2012. www.cdc.gov/niosh/docs/
wp-solutions/2013-103/ (accessed 2012 Dec 28).
78. Joint Council of Allergy, Asthma, and Immunology.
Allergen Immunotherapy Extract Preparation
Guidelines. www.jcaai.org/file_
depot/0-10000000/
20000-30000/27387/folder/62846/
Allergen_Extract_
Preparation_Guidelines.pdf (accessed 2012 Dec 28).
79. Radiopharmaceuticals for positron emission tomog-
raphy—compounding (general information chap-
ter 823). In: The United States pharmacopeia, 34th
rev., and The national formulary, 29th ed. Rockville,
MD: The United States Pharmacopeial Convention,
2011:385–9.
80. Thomas M, Sanborn MD, Couldry R. I.V. admixture
contamination rates: Traditional practice site versus a
class 1000 cleanroom. Am J Health-Syst Pharm. 2005;
62:2386–92.
81. Microbiological evaluation of clean rooms and other
controlled environments (general information chapter
1116). In: The United States pharmacopeia, 34th rev.,
and The national formulary, 29th ed. Rockville, MD:
The United States Pharmacopeial Convention; 2011:
633–41.
82. Agency for Healthcare Research and Quality Patient
Safety Network (AHRQ PSNet). Patient safety primer:
root cause analysis. www.psnet.ahrq.gov/primer.
aspx?primerID=10 (accessed 2012 Dec 28).
83. DeRosier J, Stalhandske E, Bagian JP, et al. Using
health care failure mode and effects analysis: the VA
National Center for Patient Safety’s prospective risk
analysis system. Jt Comm J Qual Improv. 2002; 28:
248–67.
Approved by the ASHP Board of Directors on June 2, 2013.
Developed through the ASHP Council on Pharmacy Practice. These